Pumitamig Expands into Kidney Cancer as BioNTech Faces a Cost-Cutting Squeeze in Berlin

BioNTech's Pumitagim enters kidney cancer trial with Arcus as German healthcare reform threatens pricing. Stock down 22% over year, but UBS upgrades on ASCO data.

BioNTech is advancing its oncology pivot on two fronts that rarely move in the same direction. On the clinical side, its lead bispecific antibody Pumitamig has secured a new combination partner for a kidney cancer trial. But back home in Germany, a sweeping healthcare reform threatens to tighten the pricing environment just as the company’s first cancer therapies approach the market.

Arcus Biosciences announced on Wednesday a collaboration with Bristol Myers Squibb that will test Pumitamig in the Phase 1/2 ROSETTA RCC-208 study for advanced renal cell carcinoma. Under the deal, Arcus supplies its HIF-2? inhibitor Casdatifan, which will be combined with Pumitamig — the PD-L1/VEGF-A bispecific jointly developed by BioNTech and BMS. Two new arms of the trial will explore a TKI-free treatment option, using Pumitamig as the backbone for combination therapy in solid tumours.

That clinical momentum comes as Berlin presses ahead with the GKV-Beitragssatzstabilisierungsgesetz (GKV-BStabG), a package of price controls and mandatory discounts designed to save the statutory health system nearly €20 billion by 2027 and more than €42 billion by 2030. BioNTech has joined a growing industry coalition protesting the plan. Eli Lilly has already warned it will halve a planned €2.5 billion investment in Germany, cutting a significant portion of 1,000 new jobs. For BioNTech, the stakes are high: favourable reimbursement terms in its home market will be critical once its oncology products reach approval. The law is expected to pass before the summer recess and take effect in January 2027.

While fighting the regulatory headwind, BioNTech is also deep in a restructuring of its own manufacturing footprint. The company is closing three German sites — Idar-Oberstein, Marburg and Tübingen — along with a facility in Singapore, all by the end of 2027. The moves affect up to 1,860 positions and are expected to generate annual savings of roughly €500 million from 2029 onward, freeing capital for the oncology pipeline. Critics note that Germany is dismantling biotech infrastructure just as the government worsens investment conditions.

The stock reflects the uncertainty. Shares traded at €76.50 on Thursday, up 0.39% on the day but down 7.27% year to date and roughly 22% lower over the past twelve months. The price remains about 28% below the 52-week high of €105.80 set in January. Analysts are divided: UBS upgraded the stock from Neutral to Buy after the ASCO 2026 data presentations, lifting its price target from $117 to $135, citing growing confidence in Pumitamig and Gotistobart. Bernstein’s Jeffrey Walch took a more cautious stance, initiating coverage with a Hold and a $96 target, implying little upside at current levels.

Behind the noise, BioNTech’s clinical pipeline is broad. The company presented data from more than 25 studies at ASCO 2026, including interim results from the ROSETTA Lung-02 trial in advanced non-small cell lung cancer. Pumitamig combined with chemotherapy delivered a 100% disease control rate across all subtypes and PD-L1 expression levels. Overall, BioNTech is running 15 Phase 3 trials, 13 of which are registration studies. A cash position of €16.8 billion and an ongoing $1 billion American Depositary Share buyback provide financial cover.

Shareholders have also strengthened oversight for the oncology era: at the May annual general meeting, Iris Löw-Friedrich and Susanne Schaffert — both with deep experience in clinical development and cancer therapy commercialisation — were elected to the supervisory board. A critical near-term milestone arrives in the third quarter, when BioNTech expects to book a €613 million payment from its BMS partnership.

Longer term, the success of the pivot will hinge on the first commercial launch of an oncology product. Co-founders Ugur Sahin and Özlem Türeci plan to step down from the management board by the end of 2026 to establish a separate mRNA research venture. Until then, the question hanging over the stock is whether Berlin’s cost-cutting drive will allow BioNTech’s pioneering cancer therapies to command the pricing they need in their most important European market.